Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a needle at the wrist calm Chemotherapy's queasiness?

NCT ID NCT07747194

Symptom relief Sponsor: Xiao Wang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether adding acupuncture at a wrist point called Neiguan to standard anti-nausea medication can reduce nausea and vomiting in people undergoing stem cell transplantation. Participants receive either real acupuncture or standard care alone during their conditioning regimen. The study aims to find a safe, non-drug way to improve comfort during cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acupuncture at Neiguan (PC6)
What this could lead to
If effective, this could offer a drug-free way to reduce nausea and vomiting during stem cell transplants, improving comfort and nutritional status.
What could go wrong
This is a small, early-stage trial, and results may not apply to all patients. Acupuncture is generally safe but may cause minor side effects like bruising or soreness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 18-65 years, either sex. Patients scheduled to receive a conditioning (preparative) regimen for hematopoietic stem cell transplantation (HSCT). Life expectancy ≥ 3 months. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment. Voluntary participation with signed informed consent. Exclusion Criteria: Received chemotherapy with highly emetogenic agents within 14 days prior to enrollment. Received radiotherapy within 7 days prior to enrollment, or planned radiotherapy during the study period. Known hypersensitivity to any study drug or its excipients. Complicated with gastrointestinal obstruction, brain metastasis with symptoms of increased intracranial pressure, or any other condition that may cause and/or exacerbate nausea and vomiting. Active infection. Unable to take oral medications. Use of any anti-emetic medication (including corticosteroids) within 48 hours or 5 half-lives of the drug (whichever is longer) prior to enrollment. Any episode of nausea, vomiting, or retching within 24 hours prior to the first administration. Severe psychiatric illness or cognitive impairment that precludes understanding, reading, and completing patient diaries. Any other condition that the investigator deems would make the patient unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced nausea and vomiting (CINV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced nausea and vomiting (CINV) Hematopoietic stem cell transplantation (HSCT)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The General Hospital of Western Theater Command

    Chengdu, Sichuan, 610083, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.